These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20492884)

  • 21. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of psoriasis with etanercept.
    Strober BE
    Semin Cutan Med Surg; 2005 Mar; 24(1):28-36. PubMed ID: 15900796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tinea versicolor associated with etanercept therapy.
    Levy MS; Polsky D; Davidson A; Strober BE
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S99-100. PubMed ID: 18489062
    [No Abstract]   [Full Text] [Related]  

  • 27. Etanercept: an overview of its role in the treatment of psoriasis.
    Galindo MP; Bartlett BL; Gewirtzman A; Mendoza N; Tremaine AM; Tyring SK
    Expert Opin Drug Metab Toxicol; 2008 Mar; 4(3):305-10. PubMed ID: 18363545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept: efficacy and safety for approved indications.
    Kerensky TA; Gottlieb AB; Yaniv S; Au SC
    Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate.
    Darabi K; Jaiswal R; Hostetler S; Bechtel M; Zirwas M
    J Drugs Dermatol; 2009 Feb; 8(2):175-8. PubMed ID: 19213235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
    Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
    J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].
    Wozel G
    Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor.
    Lee EJ; Song R; Park JN; Lee YA; Son JS; Hong SJ; Yang HI; Lee SH
    Int J Rheum Dis; 2010 Aug; 13(3):e16-9. PubMed ID: 20704604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis.
    Huo R; Romanelli P
    Am J Clin Dermatol; 2010; 11 Suppl 1():39-40. PubMed ID: 20586506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.